Alkermes (ALKS) Financials: History & Chart

Alkermes plc(ALKS)

Drug Manufacturers - Specialty & Generic · Dublin, DU

$41.71-1.05 (-2.45%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Alkermes plc

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Dublin, DU

2,050 employees

www.alkermes.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Blair Jackson

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.67B	496.01M	392.91M	384.55M	394.19M	390.66M	306.51M	429.99M	378.14M
Cost of Goods Sold	257.49M	98.11M	61.58M	46.21M	51.59M	49.46M	49.20M	62.12M	63.10M
Gross Profit	1.41B	397.90M	331.33M	338.34M	342.59M	341.20M	257.31M	367.87M	315.04M
Gross Profit Margin	84.6%	80.2%	84.3%	88.0%	86.9%	87.3%	83.9%	85.6%	83.3%
Total Operating Expenses	1.29B	379.52M	379.61M	280.23M	253.51M	248.22M	243.52M	205.18M	210.29M
Research & Development	391.04M	112.92M	103.34M	93.04M	81.74M	77.37M	71.82M	56.67M	59.89M
Selling, General & Administrative	844.46M	217.60M	264.59M	190.50M	171.77M	170.85M	171.70M	146.99M	150.38M
Operating Income (EBIT)	117.28M	18.38M	-48.28M	58.10M	89.08M	92.98M	13.79M	162.69M	104.76M
Operating Margin	7.0%	3.7%	-12.3%	15.1%	22.6%	23.8%	4.5%	37.8%	27.7%
Income Before Tax (EBT)	97.32M	-1.88M	-61.93M	60.38M	100.75M	104.84M	25.49M	169.89M	110.23M
Interest Income	37.96M	5.34M	8.54M	12.13M	11.94M	11.09M	10.14M	11.40M	10.92M
Interest Expense	59.09M	25.93M	20.89M	12.28M	N/A	N/A	N/A	4.65M	6.00M
Other Income/Expense	-19.96M	-20.25M	-13.65M	2.27M	11.66M	11.86M	11.70M	7.20M	5.47M
Net Income	66.12M	501K	-66.48M	49.34M	82.76M	87.10M	22.46M	146.50M	92.38M
Income Tax Expense	31.20M	-2.38M	4.55M	11.04M	17.98M	17.74M	3.02M	24.15M	17.43M
Net Profit Margin	4.0%	0.1%	-16.9%	12.8%	21.0%	22.3%	7.3%	34.1%	24.4%
EBITDA	178.91M	48.65M	-28.85M	61.95M	97.16M	100.80M	21.21M	169.53M	111.73M
EBITDA Margin	10.7%	9.8%	-7.3%	16.1%	24.6%	25.8%	6.9%	39.4%	29.5%
Depreciation & Amortization	61.63M	30.28M	19.43M	3.85M	8.08M	7.82M	7.42M	6.85M	6.97M
EPS Basic	0.40	0.00	-0.40	0.30	0.50	0.53	0.14	0.90	0.57
EPS Diluted	0.38	0.00	-0.40	0.29	0.49	0.52	0.13	0.88	0.55
Weighted Average Basic Shares	166.61M	166.61M	166.20M	164.70M	165.09M	164.96M	163.41M	161.96M	163.37M
Weighted Average Diluted Shares	166.61M	166.61M	166.20M	168.74M	168.51M	168.36M	168.74M	166.55M	167.03M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	1.48B	1.56B	1.66B	1.11B	1.17B	1.04B	1.17B	1.09B
Cost of Goods Sold	196.46M	245.33M	253.04M	218.07M	197.32M	178.32M	180.38M	176.42M
Gross Profit	1.28B	1.31B	1.41B	893.73M	976.43M	860.44M	990.56M	917.85M
Gross Profit Margin	86.7%	84.2%	84.8%	80.4%	83.2%	82.8%	84.6%	83.9%
Total Operating Expenses	1.03B	891.66M	996.25M	899.82M	878.68M	972.87M	1.17B	1.02B
Research & Development	323.96M	245.33M	270.81M	272.70M	290.92M	394.59M	512.83M	425.41M
Selling, General & Administrative	714.52M	645.24M	689.75M	590.75M	549.61M	538.83M	599.45M	526.41M
Operating Income (EBIT)	253.96M	420.64M	414.12M	-6.09M	97.75M	-112.43M	-175.48M	-99.13M
Operating Margin	17.2%	27.0%	24.9%	-0.5%	8.3%	-10.8%	-15.0%	-9.1%
Income Before Tax (EBT)	291.45M	443.75M	421.52M	-31.13M	87.73M	-96.54M	-197.06M	-126.97M
Interest Income	45.30M	42.45M	30.85M	7.63M	2.41M	6.96M	13.98M	9.24M
Interest Expense	12.28M	22.58M	23.03M	13.04M	11.22M	8.66M	13.60M	15.44M
Other Income/Expense	37.49M	23.11M	7.40M	-25.04M	-10.02M	15.89M	-21.58M	-27.84M
Net Income	241.66M	367.07M	355.76M	-158.27M	-48.17M	-110.86M	-196.62M	-139.31M
Income Tax Expense	49.79M	71.61M	-97.64M	2.02M	11.33M	14.32M	-436K	12.34M
Net Profit Margin	16.4%	23.6%	21.4%	-14.2%	-4.1%	-10.7%	-16.8%	-12.7%
EBITDA	281.12M	449.17M	489.05M	71.77M	176.40M	-30.57M	-95.07M	4.53M
EBITDA Margin	19.0%	28.8%	29.4%	6.5%	15.0%	-2.9%	-8.1%	0.4%
Depreciation & Amortization	27.16M	28.53M	74.93M	77.86M	78.65M	81.85M	80.41M	103.66M
EPS Basic	1.47	2.22	2.14	-0.97	-0.30	-0.70	-1.25	-0.90
EPS Diluted	1.43	2.17	2.10	-0.97	-0.30	-0.70	-1.25	-0.90
Weighted Average Basic Shares	164.70M	165.39M	166.22M	163.74M	160.94M	158.80M	157.05M	155.11M
Weighted Average Diluted Shares	168.74M	169.20M	169.73M	163.74M	160.94M	158.80M	157.05M	155.11M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.